An Open-Label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options

Trial Profile

An Open-Label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Antiretrovirals; Fosamprenavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 05 Jun 2009 New trial record.
    • 05 Jun 2009 New source identified and integrated (GlaxoSmithKline Clinical Trials Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top